- Trial Phase
- Phase 2 completed; Phase 3 registrational trial design aligned with FDA
- Time to Market
- At least 3-5 years if Phase 3 succeeds — the registrational trial has not yet started, and would need to complete before an NDA submission and FDA review.
- Why 4/10
- No hard dated binary catalyst (PDUFA or pivotal readout) is scheduled within the next ~12 months — the Phase 3 registrational trial design is aligned with FDA but the trial has not yet started. Zervimesine is essentially the company's only asset, but without a near-term binary event the stock moves on trial-initiation timelines and partnership speculation rather than a hard catalyst.
Watch for the initiation of the Phase 3 registrational trial in DLB psychosis — that will be the next major derisking event. Also monitor cash runway: with ~$37M and a Phase 3 trial ahead, a dilutive equity offering or partnership deal is likely within the next 12 months. The stock's low price (~$0.72) and high analyst targets ($3-4) reflect binary risk; position sizing should account for clinical-stage volatility.
Price Chart
Executive Summary
Zervimesine (CT1812) is Cognition Therapeutics' lead drug candidate, a sigma-2 receptor antagonist in development for dementia with Lewy bodies (DLB) psychosis — a neurodegenerative condition affecting ~1.4 million Americans with no FDA-approved treatments. Phase 2 SHIMMER data showed an 86% slowing of neuropsychiatric decline vs placebo, and the FDA has aligned on a Phase 3 registrational trial design (October 2026). The stock trades at ~$0.72 with a ~$71M market cap, with 8 of 9 analysts rating it Buy/Strong Buy and a mean price target of $3.33 (~317% upside). However, the company is pre-revenue with ~$37M cash (runway through Q2 2027), and the Phase 3 trial has not yet begun. The earlier PDUFA date (April 2026) for Alzheimer's disease passed without a clear outcome, and the company pivoted to the DLB psychosis indication where the regulatory path is now clearer.
How It Works
Zervimesine (CT1812) is a small molecule that blocks the sigma-2 receptor complex on brain cells. In Alzheimer's and dementia with Lewy bodies (DLB), toxic amyloid-beta oligomers bind to this receptor and damage synapses — the connections between neurons. By blocking this interaction, zervimesine aims to protect synapses from damage and slow cognitive and psychiatric decline. It's taken as a once-daily oral pill.
Trial Status
The Phase 2 SHIMMER study in dementia with Lewy bodies (DLB) met its primary endpoint, showing an 86% slowing of decline in neuropsychiatric symptoms (NPI-12) versus placebo over 6 months. Cognition Therapeutics received FDA alignment in October 2026 on key elements of a pivotal Phase 3 trial in DLB psychosis, including patient selection, 100 mg once-daily dose, 9-month duration, and primary endpoint (NPI2 measuring hallucinations/delusions). The Phase 3 trial has not yet been initiated. An earlier NDA filing for Alzheimer's disease had a PDUFA date of April 13, 2026, but the company has since shifted primary focus to DLB psychosis.
The Two-Sided Case
Upcoming Catalysts
- Initiation of Phase 3 registrational trial in DLB psychosis (timing TBD)
- Potential partnership or licensing deal given de-risked regulatory path
- Q3 2026 earnings call on November 18, 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
COGNITION THERAPEUTICS INC 8-K CGTX ·Originating report